Lineage Cell Therapeutics Inc (Lineage) is a clinical-stage biotechnology company that develops novel cell therapies for the treatment of unmet medical needs. The company operates through single segment that includes research and development of therapeutic products for neurological diseases, orthopedics, oncology, retinal, blood and vascular system diseases. The company carries out R&D programs based on its core proprietary cell therapy technology platforms for cell replacement and cell/drug delivery.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

The company R&D efforts focus on the development of its Cell Therapy technology product candidates for the treatment of various therapeutic indications. - In FY2022, the company spent US$13.8 million on R&D activities, which was 93.2% of the company’s revenue. As of December 2022, the company had hundreds of US and international patents and patent applications.